基于多能干细胞定向诱导分化视网膜类器官(RO)技术可以高度模拟人类视网膜的发育过程,帮助深入理解视网膜的发育机制,并为视网膜疾病提供新的治疗方法。目前,RO广泛应用于视网膜疾病的机制和治疗研究,尤其在视网膜色素变性(RP)中取得了较为突出的进展。本文总结了利用人多功能干细胞制备RO的方法,阐述了RO-RP疾病模型在 PRPF31、 RPGR、 CRB1、 RP2、 IMPG2、 NR2E3、 USH2A、 PDE6B和 TRNT1等不同突变基因中的机制与治疗应用,概括其在药物筛选、药物毒性试验、基因疗法和细胞疗法方面的研究进展,讨论了RO的研究及应用挑战。
After more than ten years of development, retinal organoid (RO) based on pluripotent stem cells can highly simulate the development process of human retina, provide insight into the mechanism of retinal development and provide new treatments for retinal diseases.At present, RO has been widely used in the research of the mechanism and treatment of retinal diseases, especially in retinitis pigmentosa (RP).This review summarizes the methods of preparing RO from human pluripotent stem cells, and elaborates the mechanism and therapeutic application of RO-RP disease model in different mutated genes such as PRPF31, RPGR, CRB1, RP2, IMPG2, NR2E3, USH2A, PDE6B and TRNT1, as well as the research progress of RO in drug screening, drug toxicity testing, gene therapy and cell therapy, and discusses the research and application challenges of RO.
谢林瑶,陈建苏,郭永龙. 基于类器官的视网膜色素变性疾病模型构建及研究进展[J]. 中华实验眼科杂志,2024,42(05):473-477.
DOI:10.3760/cma.j.cn115989-20230808-00061版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。